A randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of three dose levels of Corlux (mifepristone) plus an antidepressant vs placebo plus an antidepressant in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features (PMD).

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of three dose levels of Corlux (mifepristone) plus an antidepressant vs placebo plus an antidepressant in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features (PMD).

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 1460) assessing incidence of adrenal insufficiency with normal cortisol levels presented at The 98th Annual Meeting of the Endocrine Society.
    • 14 Feb 2012 Actual number of patients changed from 433 to 443 as reported by ClinicalTrials.gov
    • 14 Feb 2012 Actual end date (1 Jan 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top